Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1980 1
1981 2
1983 1
1984 2
1985 2
1986 1
1987 9
1988 3
1989 5
1990 5
1991 7
1992 5
1993 1
1994 3
1995 6
1996 4
1997 7
1998 5
1999 9
2000 4
2001 9
2002 13
2003 10
2004 15
2005 14
2006 18
2007 27
2008 16
2009 26
2010 26
2011 35
2012 27
2013 32
2014 40
2015 54
2016 53
2017 55
2018 66
2019 100
2020 89
2021 117
2022 97
2023 122
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

1,065 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 82gorzata, 20Tokarska-Rodak
Page 1
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs.
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Bektas M, et al. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S14-S20. doi: 10.18553/jmcp.2020.26.12-b.s14. J Manag Care Spec Pharm. 2020. PMID: 33356783 Free PMC article. Review.
The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both monoclonal antibodies designed to target the complement protein C5, thereby preventing its cleavage and the formation of the terminal at …
The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both mon …
Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.
Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, Guasch-Ferré M. Morze J, et al. Diabetes Care. 2022 Apr 1;45(4):1013-1024. doi: 10.2337/dc21-1705. Diabetes Care. 2022. PMID: 35349649 Free PMC article. Review.
Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the maj …
Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates …
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Kulasekararaj AG, et al. Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3. Blood. 2019. PMID: 30510079 Free PMC article. Clinical Trial.
Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement-inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH). ...
Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 w …
ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR. Yin C, et al. Nat Med. 2019 Mar;25(3):496-506. doi: 10.1038/s41591-018-0336-8. Epub 2019 Jan 28. Nat Med. 2019. PMID: 30692699 Free PMC article.
C1q-ApoE complexes in human ChPs, Abeta plaques, and arteries correlated with cognitive decline and atherosclerosis, respectively. Treatment with small interfering RNA (siRNA) against C5, which is formed by all complement pathways, attenuated murine ChP inflammation, Abeta …
C1q-ApoE complexes in human ChPs, Abeta plaques, and arteries correlated with cognitive decline and atherosclerosis, respectively. Treatment …
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM, Navarro-Cabrera JR, Comia NS, Goh YT, Idrobo H, Kongkabpan D, Gómez-Almaguer D, Al-Adhami M, Ajayi T, Alvarenga P, Savage J, Deschatelets P, Francois C, Grossi F, Dumagay T. Wong RSM, et al. Blood Adv. 2023 Jun 13;7(11):2468-2478. doi: 10.1182/bloodadvances.2022009129. Blood Adv. 2023. PMID: 36848639 Free PMC article. Clinical Trial.
Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for 3 months (European Union). ...
Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or int …
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, Beasley KN, Aguzzi R, Howard JF Jr. Vu T, et al. J Neurol. 2023 Jun;270(6):3129-3137. doi: 10.1007/s00415-023-11617-1. Epub 2023 Mar 9. J Neurol. 2023. PMID: 36890354 Free PMC article. Clinical Trial.
INTRODUCTION: The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. ...CONCLUSIONS: PK/PD evidence supports the use of ravulizumab every 8 weeks for immediate, complete, and sustained inhibition of ter …
INTRODUCTION: The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 …
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. Brodsky RA, et al. Haematologica. 2021 Jan 1;106(1):230-237. doi: 10.3324/haematol.2019.236877. Haematologica. 2021. PMID: 31949012 Free PMC article. Clinical Trial.
Of the five BTH events occurring in ravulizumab-treated patients across the studies, none were temporally associated with suboptimal C5 inhibition (free C5 0.5 mug/mL); four (80.0%) were temporally associated with complement-amplifying conditions (CACs). ...Six even …
Of the five BTH events occurring in ravulizumab-treated patients across the studies, none were temporally associated with suboptimal C5 …
Proteolysis-targeting chimeras with reduced off-targets.
Nguyen TM, Sreekanth V, Deb A, Kokkonda P, Tiwari PK, Donovan KA, Shoba V, Chaudhary SK, Mercer JAM, Lai S, Sadagopan A, Jan M, Fischer ES, Liu DR, Ebert BL, Choudhary A. Nguyen TM, et al. Nat Chem. 2024 Feb;16(2):218-228. doi: 10.1038/s41557-023-01379-8. Epub 2023 Dec 18. Nat Chem. 2024. PMID: 38110475 Free PMC article.
We generated a library of pomalidomide analogues to understand how functionalizing different positions of the phthalimide ring, hydrogen bonding, and steric and hydrophobic effects impact ZF protein degradation. Modifications of appropriate size on the C5 position reduced …
We generated a library of pomalidomide analogues to understand how functionalizing different positions of the phthalimide ring, hydrogen bon …
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, Sarda SP, Baver SB. Dingli D, et al. Ann Hematol. 2022 Feb;101(2):251-263. doi: 10.1007/s00277-021-04715-5. Epub 2022 Jan 1. Ann Hematol. 2022. PMID: 34973099 Free PMC article.
Current therapies for this complement-mediated disease rely predominantly on inhibition of the C5 complement protein. However, data on treatment responses and quality of life in C5-inhibitor (C5i)-treated PNH patients are scarce. ...This cross-sectional study survey …
Current therapies for this complement-mediated disease rely predominantly on inhibition of the C5 complement protein. However, data o …
1,065 results